General Oncology MIPS Specialty Measure Set (2018)

This measure set was for 2018 MIPS Quality reporting. View 2019 version ->

CMS specialty measure sets may be reported as an alternative to reporting 6 separate quality measures. If a measure set has less than 6 measures, eligible groups and clinicians must report all measures in the set. However, if a set has more than 6 measures, participants may choose the 6 measures that best fit their practice. Remember, at least one outcome measure must be reported, regardless of whether or not an outcome measure is included in a measure set.

Quality IdMeasure NameHigh PriorityMeasure TypeMeasure DescriptionFull Specifications
047Care PlanYesProcessPercentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care planRead More
102Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer PatientsNoProcessPercentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancerRead More
130Documentation of Current Medications in the Medical RecordYesProcessPercentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications’ name, dosage, frequency and route of administrationRead More
143Oncology: Medical and Radiation – Pain Intensity QuantifiedYesProcessPercentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantifiedRead More
144Oncology: Medical and Radiation – Plan of Care for PainYesProcessPercentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address painRead More
226Preventive Care and Screening: Tobacco Use: Screening and Cessation InterventionNoProcessPercentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received tobacco cessation intervention if identified as a tobacco userRead More
250Radical Prostatectomy Pathology ReportingNoProcessPercentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin statusRead More
317Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up DocumentedNoProcessPercentage of patients aged 18 years and older seen during the submitting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicatedRead More
374Closing the Referral Loop: Receipt of Specialist ReportYesProcessPercentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referredRead More
402Tobacco Use and Help with Quitting Among AdolescentsNoProcessThe percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco userRead More
431Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief CounselingNoProcessPercentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol userRead More
449HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted TherapiesNoProcessProportion of female patients (aged 18 years and older) with breast cancer who are human epidermal growth factor receptor 2 (HER2)/neu negative who are not administered HER2-targeted therapiesRead More
450Trastuzumab Received By Patients With AJCC Stage I (T1c) – III And HER2 Positive Breast Cancer Receiving Adjuvant ChemotherapyNoProcessProportion of female patients (aged 18 years and older) with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer receiving adjuvant chemotherapy who are also receiving trastuzumabRead More
451RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody TherapyNoProcessPercentage of adult patients (aged 18 or over) with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy for whom RAS (KRAS and NRAS) gene mutation testing was performedRead More
452Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal AntibodiesNoProcessPercentage of adult patients (aged 18 or over) with metastatic colorectal cancer and RAS (KRAS or NRAS) gene mutation spared treatment with anti-EGFR monoclonal antibodiesRead More
453Proportion Receiving Chemotherapy in the Last 14 Days of LifeNoProcessProportion of patients who died from cancer receiving chemotherapy in the last 14 days of lifeRead More
454Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of LifeNoOutcomeProportion of patients who died from cancer with more than one emergency room visit in the last 30 days of lifeRead More
455Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of LifeNoOutcomeProportion of patients who died from cancer admitted to the ICU in the last 30 days of lifeRead More
456Proportion Not Admitted To HospiceNoProcessProportion of patients who died from cancer not admitted to hospiceRead More
457Proportion Admitted to Hospice for less than 3 daysNoOutcomeProportion of patients who died from cancer, and admitted to hospice and spent less than 3 days thereRead More

Stay up to date with the latest news regarding MACRA and MIPS.

The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.